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Introduction 21 
Shenmai, a traditional Chinese medicine has been shown to improve cardiac function 22 
during coronary artery bypass grafting, has not yet been assessed as adjunctive treatment to be 23 
used during cardiac rehabilitation. Shenmai is a form of medication which is administered orally 24 
or intravenously. It is widely used in clinics for improving heart functions by regulating blood 25 
pressure, dilating coronary arteries, and generating antioxidative effect.1,2 Studies have 26 
demonstrated that Shenmai has a positive inotropic effect and improves exercise tolerance 27 
among patients suffering from coronary artery disease and heart failure.3,4 28 
Cardiac rehabilitation after coronary artery bypass grafting is highly recommended by the 29 
clinical practice guidelines.5 In China, however, cardiac rehabilitation is only 24% available, and 30 
only in the large medical centers, and the percentage of patients undergoing cardiac rehabilitation 31 
is relatively low.6 Due to cultural beliefs, Chinese patients are more willing to accept traditional 32 
ways of rehabilitation. For example, they are more likely to perform Taiji as a way of exercise 33 
instead of walking on a treadmill or riding an exercise bike. They also prefer traditional Chinese 34 
herbs and medicine since they are thought to be more natural, cheaper and safer.  35 
Shenmai is extracted from several Chinese herbs, mainly from Panaxginseng and 36 
Ophiopogon japonicus. It is approved by the China Food and Drug Administration since 1995.7 37 
The formula of the compound is standardized, and mass produced in two forms, capsule or 38 
injection. Considering its multi-effect on the cardiovascular system,8 Shenmai is assumed as a 39 
complement to contemporary cardiac rehabilitation after coronary artery bypass grafting. 40 
However, the effect of Shenmai as a complement to standard cardiac rehabilitation in patients 41 
who received coronary artery bypass grafting is unknown. Therefore, the aim of this study is to 42 
examine the efficacy of Shenmai as a complement to standard cardiac rehabilitation in Chinese 43 
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patients undergoing coronary artery bypass grafting, mainly in the patients with mild to moderate 44 
impaired heart function (New York Heart Association (NYHA) classification Ⅱ-Ⅲ).7,9 45 
Methods 46 
The study was conducted by Beijing Anzhen Hospital, Capital Medical University, 47 
Beijing, China. It was approved by the independent Medical Ethics Committee of Anzhen 48 
Hospital before the start (No. 2016P02). The clinical trial has been registered at Chinese Clinical 49 
Trial Registry with the name ‘The utility of Chinese traditional medicine (Shenmai) in the 50 
cardiac rehabilitation after coronary artery bypass graft: a randomized controlled trial’ and the 51 
registration number is ChiCTR1800015547. The data collection began in March 2018 and ended 52 
in May 2018. 53 
The study was a single-center randomized clinical trial. A total of 166 eligible patients 54 
received coronary artery bypass grafting were enrolled and allocated equally to the Shenmai and 55 
control group (83:83). The randomization was conducted based on random numbers generated 56 
by a random number generator from the clinical trial data management center of Anzhen 57 
Hospital and a random allocation occurred just after the recruitment. All participants received 58 
standard cardiac rehabilitation according to the clinical guidelines, while participants in the 59 
Shenmai group was treated with Shenmai (injection and capsule sequential) additionally. A 30-60 
day follow-up was completed through the outpatient’s department.  Participants were assessed at 61 
baseline, on the day of discharge and 30-day follow up. 62 
Setting and participants 63 
From March 2018 to April 2018, a total of 166 patients received coronary artery bypass 64 
grafting in our center were consecutively enrolled according to the inclusive criteria. Individuals 65 
were eligible if they were 1) 18 years old; 2) diagnosed as coronary artery disease and planned 66 
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to receive the coronary artery bypass grafting, no matter what other procedure was added 67 
simultaneously; 3) gave informed consent; 4) competent to complete the 6-minute walking test 68 
without any assistance. The patients were excluded when: 1) with severe comorbidity that can’t 69 
finish the 6-minute walking test alone, such as heart failure, stroke with severe sequela, multi-70 
organ dysfunction or disable; 2) with tumor that the predicted life time is less than 3 months. 71 
Intervention  72 
Participants in both groups received standard cardiac rehabilitation after coronary artery 73 
bypass grafting. In addition, the Shenmai group received Shenmai injections and capsules, while 74 
the control group received no additional treatment. 75 
The rehabilitation program was designed according to the clinical guidelines,10 including 76 
exercise training, focusing on aerobic exercise such as a combination of walking or jogging on a 77 
treadmill or stationary surface, stair climbing, and step aerobics. It began right after the patients 78 
could get out of bed. The intensity of the training program was established according to 79 
participants’ clinical condition and tolerance for symptom-limited exercise. Exercise training 80 
was conducted twice a day and was supervised by members of the cardiac rehabilitation staff. 81 
Each exercise session lasted up to 60 minutes (as tolerated) and included at least 5 minutes each 82 
for warm-up and cool-down exercises.11 83 
Shenmai is mainly extracted from two plants, Panaxginseng and Ophiopogon japonicus.12 84 
It  has been mass-produced as a patented drug based on the national standards approved by 85 
CFDA (China Food and Drug Administration). Shenmai injection used in our research was 86 
manufactured in accordance with applicable GMP by Qing Chunbao Pharmaceutical Co., Ltd 87 
(Hangzhou, China). It was administrated during the inpatient period (100ml/day). Shenmai 88 
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capsule was manufactured by Xinbang Pharmaceutical Co., Ltd (Guizhou, China) and was 89 
prescribed after the day discharged from our hospital and back to home (3.6g/day). 90 
Measurements 91 
These baseline clinical outcomes data were collected based on medical record, which 92 
include age, gender, body mass index (BMI), smoking history, family history of coronary artery 93 
disease, et al. 94 
The 6-minute walking test was implemented at three time points. The first point was on 95 
the day just before the operation. The second point was on the day when participants were 96 
discharged from the hospital and sent home. The third point was on the last day of 30-day, post-97 
discharge follow-up. The first and second measurements were conducted in-hospital. For the 98 
third (follow-up) test, all participants were required to return to the outpatient clinic to perform 99 
the walking test.  100 
The 6-minute walking test was conducted by two special assistant investigators. They 101 
instructed the participants to implement the test and measured the distance. They were 102 
supervised by research team members during the entire measurement to ensure their blindness to 103 
the allocation.  104 
The patients were instructed to walk as far as possible along a 20-m straight, flat hospital 105 
corridor in 6 minutes. Patients who showed any uncomfortable symptoms (e.g. angina, severe 106 
dyspnea, dizziness and musculoskeletal pain) were told to stop or slow their walking and to 107 
restart if symptoms disappeared within 6 minutes. The participants were not encouraged to go 108 
beyond their tolerance by researchers. The total distance walked was measured to the nearest 109 
meter of integer and recorded.  110 
Clinical outcomes.  111 
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The primary outcome was the distance of 6-minute walking test on the point of discharge; 112 
The secondary outcomes related to the safety and efficiency of the intervention, such as 113 
perioperative and follow-up mortality, MI, stroke, reoperation, the length of stay in ICU, the 114 
duration under the mechanical ventilation and the length of stay after the operation in hospital. 115 
The distance of 6-minute walking test at the point of 30-day follow up was also a secondary 116 
endpoint in this study. 117 
Sample size calculation 118 
The sample size was estimated based on the expected improvement in the distance of 6-119 
minute walking test on the day of discharge through the previous clinic trial that applied 120 
Shenmai in the patients with heart failure.3 It was expected that a 32 meters improvement in 121 
Shenmai group and the standard deviation (SD) of 65 meters was derived from previous study. 122 
Given a power (1-β) of 80% and α = 0.05 (two-side), 66 patients would be required for each 123 
group to detect the superiority. Moreover, considering the dropout rate was approximately 20%, 124 
a total of 166 patients (83 per treatment group) was needed to be randomized to achieve the 125 
required number of patients for the efficacy analysis. 126 
Statistical analysis 127 
Statistical analyses were performed using the R statistical package (R version 3.4.2 128 
(2017-09-28)). The continuous variables were calculated for mean and standard deviations. 129 
Comparison of normal distributed data from the patients who completed both initial and follow-130 
up exercise test was performed using the Student's t-test between two groups. The non-normally 131 
distributed data was analyzed using the Wilcoxon rank sum test. Categorical variables were 132 
presented as counts and percentages. The differences in categorical variables between patient 133 
subgroups were evaluated with chi-square test or Fisher exact test as appropriate.  134 
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Linear mixed model was performed with SAS version 9.4 (SAS Institute, Cary, NC) to 135 
examine the differences of 6-min walking distance between two groups over time. A two-tailed p 136 
value < 0.05 was considered statistically significant. Intension to treat principle was performed, 137 
that is, we still included participants for data analysis if they withdrew study.  138 
Results 139 
This trial was implemented according to the flow diagram (Figure 1). From March 2018 140 
to April 2018, a total of 213 patients were approached, but only 166 were recruited and allocated 141 
randomly into two equal groups. All participants completed the clinical data collection along 142 
with the basal 6-minute walking test. The participants of Shenmai group were administrated the 143 
Shenmai injection right after the surgery for 9.28 ± 3.75 days and then changed to the Shenmai 144 
capsule for 30 days. Only two suffered from severe surgical complications, the other 164 patients 145 
accomplished the 6-minute walking test on discharge and 30-day follow up. No participants 146 
dropped out during the follow up.  147 
The demographic characteristic of the study cohort was shown in Table 1. The sample 148 
(n=166) was predominately male (84%). The mean age was 61.12 ± 9.13 years. The baseline 149 
characteristics between two groups were roughly equal. The procedural characteristics were also 150 
comparable (Table 2).  151 
The post-operative outcomes of the study were shown in Table 3. There was one death in 152 
the control group, owing to the postoperative myocardial infarction (MI) and acute heart failure. 153 
It happened the day after the operation and appeared as progressive hypotension. The 154 
electrocardiogram and myocardial enzyme helped make the final diagnosis (the cardiac troponin 155 
I was greater than the upper bound (85ng/l) of the test kit). An intensive therapy was 156 
administered shortly after, including the intra-aortic balloon pump (IABP), but failed. A patient 157 
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in the Shenmai group suffered severe stroke and couldn’t extubate in the ICU. After prolonged 158 
hours of mechanical ventilation and length of stay in the ICU, this patient was transferred to the 159 
department of Neurology to receive rehabilitation. There was no other death, stroke, MI and 160 
reoperation during the in-hospital stage. The duration of the length of stay in ICU of the entire 161 
cohort was 62.64 ± 58.40 [95% CI: 53.69, 71.59] hours. The hours of mechanical ventilation 162 
were 16.07 ± 32.54 [95% CI: 11.06, 21.09]. There was no death, stroke, MI, reoperation, or 163 
rehospitalization in the period of follow up.  164 
The 6-minute walking test was implemented according to the protocol. The baseline 165 
distance of the two groups before the operation was comparable. As shown in the linear mix 166 
model analysis, there were group (p =.005) and time points of measurement (p<.001) effects on 167 
the 6-min walking distance. However, there was no interaction effect between group and time 168 
points of measurement. Participants in the Shenmai group walked longer distance in meters 169 
compared with the control group on the day of discharge (314.54 ± 64.14 vs. 271.29 ± 76.82, 170 
P<0.001), while there were no significant differences before operation (399.72± 93.19 vs. 403.67 171 
± 91.99, p=.78) or on the 30-day follow-up (436.54 ± 67.64 vs. 421.64 ± 83.53, p=.21). Also, 172 
there was greater improvement at the point of 30-day follow-up compared to the point of pre-173 
operation and discharge in both groups (ps<.001) (table 4). These differences were maintained 174 
after adjusting for age, gender, BMI, smoking history and post-operation length of stay in 175 
hospital. The post-operation length of stay in hospital was slightly longer in Shenmai group than 176 
control group (9.28 ± 3.75 days vs. 8.60 ± 2.50 days) and might have influence on the exercise 177 
tolerance comparison at discharge; however, the conclusion did not change after adjusting this 178 
confounder.   179 
Discussion 180 
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As shown in this study, Shenmai significantly improved the exercise tolerance at the end 181 
of the in-hospital stage of cardiac rehabilitation. At the 30-day follow-up, the Shenmai group 182 
reached a greater distance in the 6-minute walking test compared with the control group, but 183 
there was no statistically significant difference. Other outcomes were comparable between the 184 
two groups and no side effects were experienced by the Shenmai group.  185 
Shenmai is widely used in China as a complementary treatment for either acute or 186 
chronic heart failure. It is extracted from Panax ginseng and Ophiopogon japonicus and usually 187 
mass-produced as a patented drug in different forms (including capsule, powder, oral liquid and 188 
injection) based on a standardized formula. In clinical practice, Shenmai is used to ease the 189 
symptoms and discontinued after the relief of symptoms or in the case of disease remission. 190 
Adverse effects are rare and mild; an allergic reaction is most common.13 191 
In this study, we administrated Shenmai in the cardiac rehabilitation after coronary artery 192 
bypass grafting. An exercise improvement was achieved in the early postoperative stage. 193 
Although the key ingredient in Shenmai is complex and not very clear, the study indicated the 194 
potential mechanism in five aspects, including positive inotropic effect,1 dual-directional 195 
regulation on blood pressure,14 improving hemodynamic parameters,15 delaying the cardiac 196 
remodeling,2 and antioxidative effect.16 The cure effect is also shown in many other aspects, such 197 
as reduction of the mortality, improvement of function classification according to the New York 198 
Heart Association (NYHA), and decrease of the adverse effects.13 199 
Similar to other traditional Chinese medicines, Shenmai is too obscure to be understood 200 
based on traditional Chinese medicine theory. Then inevitably, we will ask why a significant 201 
difference in the 6-minute walking test was not demonstrated on the 30-day follow-up between 202 
two groups? Does it mean that Shenmai has no effect on the cardiac rehabilitation at all, even 203 
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though the significant improvement was shown at discharge? When looking insight into this 204 
study, two major facts should be paid attention. Considering the study design, the point of 205 
discharge is the primary endpoint, the 30 days outcome is secondary endpoint. Perhaps the 206 
efficacy of study design is insufficient for a positive outcome at 30-day follow up, because the 207 
sample size calculation is based on information at the time point of discharge. Further study will 208 
focus on the long-term follow up based on the data demonstrated by this trial. The second 209 
possible reason was the change of Shenmai from injections to capsules when discharged. The 210 
capsule of Shenmai needs much more time and dosage to show its cure effect. The third possible 211 
reason is that we did not provide placebo to the control group, which might confound results.  212 
Chinese herbs and medicine closely relate to the cultural belief that traditional Chinese 213 
medicine is more natural, effective, cheap and has fewer adverse effects. In the traditional 214 
Chinese medicine theory, when treating the patient as an entirety, the ‘Qi’ deficiency is the 215 
critical factor during the cardiac rehabilitation. Many methods from traditional Chinese medicine 216 
have been used in the exercise prescription of cardiac rehabilitation to improve the deficiency, 217 
such as Taiji and Ba Duanjin. Given this study and others, Shenmai also showed significant 218 
benefit in improving the exercise tolerance.3 Many other treatment ways originated from the 219 
traditional Chinese medicine have similar efficacy. Future study needs examine long-term effect 220 
and the effective ingredients in Shenmai, which need to be purified and fixed.   221 
 222 
Clinical messages 223 
• Shenmai improves the exercise tolerance in the early stage of the cardiac rehabilitation 224 
according to this study. It is safe and effective when administrated to patients who 225 
received coronary artery bypass grafting.  226 
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• The traditional Chinese medicine can be complementary to the standard cardiac 227 
rehabilitation.    228 
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 240 
Table.1. Clinical demographics characteristics of patients 241 
 Control (n=83) Shenmai (n=83) P value 
Sex (male %)* 69 (83) 70 (84) 0.83 
Age (year)# 61.69 ± 8.60 60.55 ± 9.65 0.42 
BMI (kg/m2)# 25.30 ± 3.24 25.71 ± 3.01 0.39 
Smoking history (%)* 45 (54) 47 (57) 0.75 
Family history of CAD 
(%)ꝉ* 
6 (7) 4 (5) 0.75 
Pre-MI (%)* 52 (63) 38 (46) 0.029 
DM (%)* 23 (28) 26 (31) 0.61 
Hyperlipoidemia (%)* 49 (59) 49 (59) 1.00 
Hypertension (%)* 55 (66) 50 (60) 0.42 
Stroke (%)* 7 (8) 7 (8) 1.00 
Renal disfunction (%)ꝉ* 2 (2) 1 (1) 1.00 
PVD (%)ꝉ* 0 (0) 1 (1) 1.00 
NYHA    
Ⅰ (%)ꝉ* 3 (4) 1 (1) 0.62 
Ⅱ (%)* 53 (64) 62 (75) 0.13 
Ⅲ (%)* 26 (31) 19 (23) 0.22 
Ⅳ (%)ꝉ* 1 (1) 1 (1) 1.00 
LVEF (%)ⱡ* 57.69 ± 8.79 58.53 ± 9.77 0.44 
LM disease (%)* 35 (42) 30 (36) 0.22 
Creatinine (umol/L)ⱡ# 89.17 ± 22.87 87.72 ± 19.18 0.67 
TC (mmol/L)# 4.34 ± 1.00 4.12 ± 1.15 0.66 
ALB (g/L)ⱡ# 39.66 ± 4.35 40.60 ± 3.94 0.09 
hs-CRP (ug/L)ⱡ# 3.08 ± 3.84 2.1 ± 2.22 0.20 
BMI: body mass index; MI: myocardial infarction; DM: Diabetes mellitus; PVD: peripheral 242 
vascular disease; NYHA: New York Heart Association Functional Classification; LVEF: left 243 
ventricular ejection fraction; LM: left main coronary artery; TC: total cholesterol; ALB: serum 244 
albumin; hs-CRP: high-sensitivity C-reactive protein;  245 
ꝉ: Fisher's exact test; ⱡ: Wilcoxon rank sum test 246 
*: number of patients (percentage) 247 
#: mean ± standard deviation (SD) 248 
  249 
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 250 
Table.2. Characteristics of intraoperation 251 
 Control (n=83) Shenmai (n=83) P value 
On pump CABG (%)* 41 (49) 42 (51) 0.88 
CPB time (mins)ꝉ# 117.10 ± 31.69 112.79 ± 28.50 0.60 
Clamp occlusion time# 78.34 ± 25.03 73.5 ± 24.51 0.38 
Simultaneous heart 
valve surgery (%)* 
7 (8) 7 (8) 1.00 
LIMA in use (%)* 62 (75) 68 (82) 0.26 
No. of SVG grafts    
SVG grafts = 1 (%)* 12 (14) 18 (22) 0.23 
SVG grafts = 2 (%)* 29 (35) 37 (45) 0.20 
SVG grafts = 3 (%)* 33 (40) 23 (28) 0.10 
SVG grafts = 4 (%)ⱡ* 8 (10) 2 (2) 0.10 
CABG: coronary artery bypass grafting; CPB: cardiopulmonary bypass; LIMA: left internal 252 
mammary artery; SVG: saphenous vein graft;  253 
ꝉ: Wilcoxon rank sum test; ⱡ: Fisher's exact test 254 
*: number of patients (percentage) 255 
#: mean ± standard deviation (SD) 256 
  257 
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 258 
Table.3. Differences in Postoperative Outcomes Between Groups 259 
 Control (n=83) Shenmai (n=83) P value 
Mortality (%)ꝉ* 1 (1) 0 1.00 
Stroke (%)ꝉ* 0 1 (1) 1.00 
ICU LOS (hours)ⱡ# 59.01 ± 38.67 66.28 ± 73.09 0.82 
Mechanical ventilation 
(hours)ⱡ# 
13.90 ± 9.88 18.24 ± 44.99 0.63 
Postoperative LOS in 
hospital (day)ⱡ# 
8.60 ± 2.50 9.28 ± 3.75 0.43 
ICU: intensive care unit; LOS: length of stay;  260 
ꝉ: Fisher's exact test; ⱡ: Wilcoxon rank sum test 261 
*: number of patients (percentage) 262 
#: mean ± standard deviation (SD) 263 
  264 
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 265 
Table.4. Differences in Six-Minute Walking Test Between Groups over Time 266 
 Control (n=83) Shenmai (n=83) 
 P-values  
group x time group time 
6MWT distance 
before surgery 
(meters) # 
399.72 ± 93.19 403.67 ± 91.99 0.07 0.005 <0.001 
6MWT distance 
at discharge 
(meters) # 
271.29 ± 76.82 314.54 ± 64.14  
 
 
6MWT distance 
at 30-day follow 
up (meters) # 
421.64 ± 83.53 436.54 ± 67.64  
 
 
6MWT: six-minute walking test; P-values for between group differences before surgery, at 267 
discharge and 30-day follow-up was 0.78, <.001 and 0.21, respectively. These differences were 268 
maintained after adjusting for age, gender, BMI, smoking history and post-operation length of 269 
stay in hospital.  270 
#: mean ± standard deviation (SD) 271 
  272 
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Figure 1. Flow diagram of the trial  273 
 274 
CABG: coronary artery bypass grafting; MI: myocardial infarction; ICU: intensive care unit; 275 
6MWT: 6-minute walking test; 276 
  277 
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